Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

The network is called Lunar Surface Communication System (LSCS), and it is basically a replica of the 4G/LTE cellular technology currently used on a very large scale by the humans of Earth.

It looks like T-Mobile is now accepting customers into the free beta program for SpaceX’s cellular Starlink service—but only if you have the latest Samsung handsets. On Tuesday, a number of T ...

In his book The Mathematical Universe, mathematician William Dunham wrote of John Venn’s namesake legacy, the Venn diagram, “No one in the long history of mathematics ever became better known ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said. A ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...

20. J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...